Lori A. Leslie

Phase 1b dose-finding study of rituximab, lenalidomide, and ibrutinib (R2I) in patients with relapsed/refractory mantle cell lymphoma.

A. Goy, T. Feldman, A. Petrillo, 2023, Leukemia & lymphoma.

Three-year follow-up analysis of axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma (ZUMA-5)

S. de Vos, C. Jacobson, S. Neelapu, 2023, Blood.

Subsequent Malignancies after CD19-Targeted Chimeric Antigen Receptor T cells in Patients with Lymphoma

R. Shouval, M. Palomba, M. Scordo, 2024, Transplantation and Cellular Therapy.